NCT00084747 · OUTCOME

Overall Survival

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma · Source last updated 2020-08-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: Full Range
Time frame: up to 5 years from time of consent

Groups in this outcome

Bortezomib

bortezomib

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Bortezomib	30

Reported measurements

Source class 1

Values in months · Interval/dispersion: Full Range
Group	Value	Spread	Lower	Upper	Comment
Bortezomib	55	Not reported	16	86	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
16
upper Limit
86
value
55

denoms

counts
group Id
OG000
value
30
units
Participants

dispersion Type

Full Range

groups

description
bortezomib
id
OG000
title
Bortezomib

param Type

MEDIAN

reporting Status

POSTED

time Frame

up to 5 years from time of consent

title

Overall Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice